September 28, 2020

The Niche

Knoepfler lab stem cell blog

Astellas Institute for Regenerative Medicine.

1 min read

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease’ in Nature Neuroscience. Using IPS cells for insights. “What open chromatin features predict pluripotency?” asked and answered by the authors of this review …Read More

2 min read

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial cells (RPEs) for treatment of multiple kinds of macular degeneration. These products were advancing in promising clinical trials and had demonstrated good safety profiles. After the purchase of Ocata by …Read More